Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Rosell

Showing results (61-70 of 565) with videos related to

Pageof 57
Sort By:
Onkologie|June 9, 2012
[Therapeutic standards and perspectives for stage IV non-small cell lung cancer]Martin Reck, Rafael Rosell, Markus Tiemann
Seminars in Oncology|February 1, 2017
Advances in the treatment of non-small cell lung cancer: Molecular markers take the stageRafael Rosell, Mark Green, Paul Gumerlock
Anticancer Research|January 10, 2014
Platinum drugs and DNA repair mechanisms in lung cancerLaura Bonanno, Adolfo Favaretto, Rafael Rosell
Journal of the National Cancer Institute|May 16, 2002
Re: Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancerMariano Monzo, Miquel Taron, Rafael Rosell
The Lancet. Respiratory Medicine|June 2, 2020
Targeting MET amplification in EGFR-mutant non-small-cell lung cancerRafael Rosell, Imane Chaib, Mariacarmela Santarpia
Expert Review of Anticancer Therapy|January 28, 2017
Beyond platinum treatment for NSCLC: what does the future hold?Mariacarmela Santarpia, Niki Karachaliou, Rafael Rosell
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 9, 2008
Reflections on the IASLC 12th World Conference on Lung CancerRosario Perona, Bartomeu Massuti, Rafael Rosell
European Journal of Cancer (Oxford, England : 1990)|April 7, 2021
Poziotinib treatment in intractable NSCLC: Epidermal growth factor receptor and human epidermal growth factor receptor 2 exon 20 insertion mutation diseaseRafael Rosell, Andres F Cardona Zorrilla
Lung Cancer (Amsterdam, Netherlands)|December 14, 2002
Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancerRafael Rosell, Frank Fossella, Luka Milas, et al.
Expert Review of Clinical Pharmacology|June 13, 2015
Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancerMariacarmela Santarpia, Nuno Gil, Rafael Rosell
Pageof 57

Showing results (61-70 of 565) with videos related to

Sort By:
Pageof 57
Onkologie|June 9, 2012
[Therapeutic standards and perspectives for stage IV non-small cell lung cancer]Martin Reck, Rafael Rosell, Markus Tiemann
Seminars in Oncology|February 1, 2017
Advances in the treatment of non-small cell lung cancer: Molecular markers take the stageRafael Rosell, Mark Green, Paul Gumerlock
Anticancer Research|January 10, 2014
Platinum drugs and DNA repair mechanisms in lung cancerLaura Bonanno, Adolfo Favaretto, Rafael Rosell
Journal of the National Cancer Institute|May 16, 2002
Re: Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancerMariano Monzo, Miquel Taron, Rafael Rosell
The Lancet. Respiratory Medicine|June 2, 2020
Targeting MET amplification in EGFR-mutant non-small-cell lung cancerRafael Rosell, Imane Chaib, Mariacarmela Santarpia
Expert Review of Anticancer Therapy|January 28, 2017
Beyond platinum treatment for NSCLC: what does the future hold?Mariacarmela Santarpia, Niki Karachaliou, Rafael Rosell
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 9, 2008
Reflections on the IASLC 12th World Conference on Lung CancerRosario Perona, Bartomeu Massuti, Rafael Rosell
European Journal of Cancer (Oxford, England : 1990)|April 7, 2021
Poziotinib treatment in intractable NSCLC: Epidermal growth factor receptor and human epidermal growth factor receptor 2 exon 20 insertion mutation diseaseRafael Rosell, Andres F Cardona Zorrilla
Lung Cancer (Amsterdam, Netherlands)|December 14, 2002
Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancerRafael Rosell, Frank Fossella, Luka Milas, et al.
Expert Review of Clinical Pharmacology|June 13, 2015
Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancerMariacarmela Santarpia, Nuno Gil, Rafael Rosell
Pageof 57